JP2016526016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526016A5 JP2016526016A5 JP2016512011A JP2016512011A JP2016526016A5 JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5 JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016512011 A JP2016512011 A JP 2016512011A JP 2016526016 A5 JP2016526016 A5 JP 2016526016A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr1
- medicament according
- medicament
- ecd
- fusion molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US61/818,220 | 2013-05-01 | ||
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| US61/831,029 | 2013-06-04 | ||
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526016A JP2016526016A (ja) | 2016-09-01 |
| JP2016526016A5 true JP2016526016A5 (https=) | 2017-06-15 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512011A Pending JP2016526016A (ja) | 2013-05-01 | 2014-04-30 | がんを治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (https=) |
| EP (1) | EP2991669A2 (https=) |
| JP (1) | JP2016526016A (https=) |
| KR (1) | KR20160003141A (https=) |
| CN (1) | CN105188732A (https=) |
| AU (1) | AU2014259956A1 (https=) |
| BR (1) | BR112015027607A8 (https=) |
| CA (1) | CA2908391A1 (https=) |
| HK (1) | HK1213817A1 (https=) |
| MX (1) | MX2015015115A (https=) |
| RU (1) | RU2015150233A (https=) |
| SG (1) | SG11201508878WA (https=) |
| WO (1) | WO2014179448A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP2015505818A (ja) | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2626679C (en) * | 2005-11-04 | 2011-08-16 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP5945277B2 (ja) * | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ１細胞外ドメイン併用療法 |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| JP2015505818A (ja) * | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
-
2014
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526016A5 (https=) | ||
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Wood et al. | Molecular histology of lung cancer: from targets to treatments | |
| Peltomäki | Mutations and epimutations in the origin of cancer | |
| Lee et al. | Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers | |
| Memon et al. | The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients | |
| Custodio et al. | Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study | |
| Buss et al. | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants | |
| JP2015505818A5 (https=) | ||
| JP2019509739A5 (https=) | ||
| JP2016169229A5 (https=) | ||
| Pérez-Ramírez et al. | Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer | |
| IL259672B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| Sato et al. | Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel | |
| Hui et al. | Semaphorin 3C as a therapeutic target in prostate and other cancers | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| Zhou et al. | Gene microarray analysis of lncRNA and mRNA expression profiles in patients with hypopharyngeal squamous cell carcinoma | |
| Yang et al. | Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy | |
| Lee et al. | ERBB2 kinase domain mutation in the lung squamous cell carcinoma | |
| Donaires et al. | E2F transcription factors associated with up-regulated genes in glioblastoma | |
| WO2015180488A1 (zh) | Pik3ca基因突变检测试剂盒 | |
| Jiang et al. | The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer | |
| Walter et al. | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma | |
| Tan et al. | Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients | |
| JP2013528599A5 (https=) |